Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

716
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
716
Local Anesthetics: Differential Sensitivity of Nerve Fibers01:24

Local Anesthetics: Differential Sensitivity of Nerve Fibers

1.6K
Local anesthetics (LAs) block the sodium channels of nerve trunks, sensory nerve endings, and neuromuscular junctions. Although LAs can block all kinds of nerves, the sensitivity of nerve fibers differs according to nerve types and structures. LAs are known to block myelinated fibers faster than unmyelinated ones. Also, they block pain or sensory neurons at low concentrations without affecting the motor neurons involved in muscle contractions. This helps relieve labor pain without affecting the...
1.6K
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

961
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
961
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

415
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
415
Restless Leg Syndrome and Night Terrors01:27

Restless Leg Syndrome and Night Terrors

742
Restless Leg Syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an uncontrollable urge to move the legs due to uncomfortable sensations. These sensations typically occur during periods of rest or inactivity, particularly when lying down or sitting, and can severely disrupt sleep.
The exact cause of RLS is not fully understood, but it is believed to involve dopamine, a neurotransmitter that helps regulate muscle movement. Imbalances in dopamine levels...
742
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

295
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
295

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutaneous Pili Migrans in a 17-Month-Old Girl: Not to Be Confused with Cutaneous Larva Migrans.

Turkish archives of pediatrics·2026
Same author

Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies.

The Journal of allergy and clinical immunology·2025
Same author

European S2k Guideline on Chronic Pruritus

Acta dermato-venereologica·2025
Same author

Clinical practice guidelines for the diagnosis and treatment of scabies.

International journal of dermatology·2024
Same author

Evaluation of the Quality of Life and the Demographic and Clinical Characteristics of Patients With Pemphigus With Oral Mucosal İnvolvement: A Multicenter Observational Study.

Dermatology practical & conceptual·2024
Same author

Chronic prurigo: Insufficient disease control in spite of high healthcare usage.

Journal of the European Academy of Dermatology and Venereology : JEADV·2023

Related Experiment Video

Updated: Mar 15, 2026

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
04:59

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

Published on: September 27, 2019

13.2K

Neurologic Itch Management.

Ekin Şavk1

  • 1Department of Dermatology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey.

Current Problems in Dermatology
|September 1, 2016
PubMed
Summary

Neurologic itch, or neuropathic itch, stems from nervous system dysfunction and often resists standard treatments. Effective management requires a tailored approach, potentially including pharmacotherapy, physical modalities, or surgery, depending on the cause.

Area of Science:

  • Neurology
  • Dermatology
  • Neuroscience

Background:

  • Neurologic itch, defined as pruritus from nervous system dysfunction, is often neuropathic in origin.
  • Causes range from localized nerve entrapment to widespread small nerve fiber degeneration.
  • Conventional antipruritics like antihistamines and corticosteroids are frequently ineffective for neuropathic itch.

Purpose of the Study:

  • To review the definition, causes, and current treatment strategies for neuropathic itch.
  • To highlight the limitations of existing therapies and explore novel approaches.
  • To emphasize the importance of a neurologist-guided, etiology-specific treatment plan.

Main Methods:

  • Literature review of studies on neuropathic itch.
  • Analysis of current pharmacologic and non-pharmacologic treatment options.

More Related Videos

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses
09:07

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses

Published on: June 14, 2020

11.8K

Related Experiment Videos

Last Updated: Mar 15, 2026

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors
04:59

Cheek Injection Model for Simultaneous Measurement of Pain and Itch-related Behaviors

Published on: September 27, 2019

13.2K
Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K
Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses
09:07

Mouse Footpad Inoculation Model to Study Viral-Induced Neuroinflammatory Responses

Published on: June 14, 2020

11.8K
  • Discussion of emerging therapeutic modalities.

    • Main Results:

    • Neuropathic itch requires specialized management beyond standard antipruritic medications.
    • Effective treatments include topical agents (capsaicin, tacrolimus), systemic anticonvulsants (gabapentin, pregabalin), physical modalities (TENS, phototherapy), and surgery for specific causes.
    • Various novel treatments are under investigation, including transcranial magnetic stimulation and cannabinoid receptor agonists.

    Conclusions:

    • Neuropathic itch management is complex and necessitates a personalized, multi-modal strategy.
    • Collaboration with neurologists is crucial for accurate diagnosis and effective treatment planning.
    • Ongoing research into new therapies offers hope for improved patient outcomes.